BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaufman A, Abuqayyas L, Denney WS, Tillman EJ, Rolph T. AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. Cell Rep Med 2020;1:100057. [PMID: 33205064 DOI: 10.1016/j.xcrm.2020.100057] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Ziqubu K, Mazibuko-mbeje SE, Mthembu SXH, Mabhida SE, Jack BU, Nyambuya TM, Nkambule BB, Basson AK, Tiano L, Dludla PV. Anti-Obesity Effects of Metformin: A Scoping Review Evaluating the Feasibility of Brown Adipose Tissue as a Therapeutic Target. IJMS 2023;24:2227. [DOI: 10.3390/ijms24032227] [Reference Citation Analysis]
2 Jin L, Yang R, Geng L, Xu A. Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications. Annu Rev Pharmacol Toxicol 2023;63:359-82. [PMID: 36100222 DOI: 10.1146/annurev-pharmtox-032322-093904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Le TDV, Fathi P, Watters AB, Ellis BJ, Bozadjieva-Kramer N, Perez MB, Sullivan AI, Rose JP, Baggio LL, Koehler J, Brown JL, Bales MB, Nwaba KG, Campbell JE, Drucker DJ, Potthoff MJ, Seeley RJ, Ayala JE. Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets. bioRxiv 2023:2023. [PMID: 36711605 DOI: 10.1101/2023.01.03.522509] [Reference Citation Analysis]
4 Chen Z, Yang L, Liu Y, Huang P, Song H, Zheng P. The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol 2022;13:1089214. [PMID: 36618930 DOI: 10.3389/fphar.2022.1089214] [Reference Citation Analysis]
5 Fu Z, Nilsson AK, Hellstrom A, Smith LE. Retinopathy of prematurity: Metabolic risk factors. eLife 2022;11. [DOI: 10.7554/elife.80550] [Reference Citation Analysis]
6 Vecchiatto B, de Castro TL, Muller CR, Azevedo-martins AK, Evangelista FS. Physical Exercise-Induced FGF-21 to Fight Obesity: An Update Review. Obesities 2022;2:372-379. [DOI: 10.3390/obesities2040031] [Reference Citation Analysis]
7 Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol 2022; 28(35): 5129-5140 [DOI: 10.3748/wjg.v28.i35.5129] [Reference Citation Analysis]
8 Jin T. Fibroblast growth factor 21 and dietary interventions: what we know and what we need to know next. Medical Review 2022;0. [DOI: 10.1515/mr-2022-0019] [Reference Citation Analysis]
9 Wong C, Dash A, Fredrickson J, Lewin-Koh N, Chen S, Yoshida K, Liu Y, Gutierrez J, Kunder R. Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial. Hepatology 2022. [PMID: 35993161 DOI: 10.1002/hep.32742] [Reference Citation Analysis]
10 Kaur N, Gare SR, Shen J, Raja R, Fonseka O, Liu W. Multi-organ FGF21-FGFR1 signaling in metabolic health and disease. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.962561] [Reference Citation Analysis]
11 Pedersen AKN, Hage C, Jessen N, Mellbin L, Bjerre M. Sitagliptin reduces FAP-activity and increases intact FGF21 levels in patients with newly detected glucose abnormalities. Mol Cell Endocrinol 2022;556:111738. [PMID: 35926756 DOI: 10.1016/j.mce.2022.111738] [Reference Citation Analysis]
12 Teng T, Qiu S, Zhao Y, Zhao S, Sun D, Hou L, Li Y, Zhou K, Yu X, Yang C, Li Y. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:7841. [PMID: 35887189 DOI: 10.3390/ijms23147841] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Szczepańska E, Glinicki P, Zgliczyński W, Słowińska-srzednicka J, Jastrzębska H, Gietka-czernel M. FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism. Front Endocrinol 2022;13:900034. [DOI: 10.3389/fendo.2022.900034] [Reference Citation Analysis]
14 Ornitz DM, Itoh N. New developments in the biology of fibroblast growth factors. WIREs Mech Dis 2022;14:e1549. [PMID: 35142107 DOI: 10.1002/wsbm.1549] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
15 Ott F, Körner C, Werner K, Gericke M, Liebscher I, Lobsien D, Radrezza S, Shevchenko A, Hofmann U, Kratzsch J, Gebhardt R, Berg T, Matz-soja M. Hepatic Hedgehog Signaling Participates in the Crosstalk between Liver and Adipose Tissue in Mice by Regulating FGF21. Cells 2022;11:1680. [DOI: 10.3390/cells11101680] [Reference Citation Analysis]
16 Jeon H, Lee A, Ha K. Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications. BioChip J. [DOI: 10.1007/s13206-022-00057-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Balakrishnan R, Thurmond DC. Mechanisms by Which Skeletal Muscle Myokines Ameliorate Insulin Resistance. Int J Mol Sci 2022;23:4636. [PMID: 35563026 DOI: 10.3390/ijms23094636] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
18 Szczepańska E, Gietka-Czernel M. FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. Horm Metab Res 2022;54:203-11. [PMID: 35413740 DOI: 10.1055/a-1778-4159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
19 Pan T, Li T, Shi L, Su L, Chen Y. Paracrine Fibroblast Growth Factor-Based Therapy: An Unexpected Panacea for Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD). Infectious Microbes and Diseases 2022;4:13-19. [DOI: 10.1097/im9.0000000000000083] [Reference Citation Analysis]
20 Bazarbashi N, Miller M. Triglyceride-Rich Lipoproteins. Contemporary Cardiology 2022. [DOI: 10.1007/978-3-030-98824-1_12] [Reference Citation Analysis]
21 Walth-hummel AA, Herzig S, Rohm M. Nuclear Receptors in Energy Metabolism. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-031-11836-4_4] [Reference Citation Analysis]
22 Dorval L, Knapp BI, Majekodunmi OA, Eliseeva S, Bidlack JM. Mice with high FGF21 serum levels had a reduced preference for morphine and an attenuated development of acute antinociceptive tolerance and physical dependence. Neuropharmacology 2022;202:108858. [PMID: 34715121 DOI: 10.1016/j.neuropharm.2021.108858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Kim TH, Hong DG, Yang YM. Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism. Biomedicines 2021;9:1903. [PMID: 34944728 DOI: 10.3390/biomedicines9121903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sommakia S, Almaw NH, Lee SH, Ramadurai DKA, Taleb I, Kyriakopoulos CP, Stubben CJ, Ling J, Campbell RA, Alharethi RA, Caine WT, Navankasattusas S, Hoareau GL, Abraham AE, Fang JC, Selzman CH, Drakos SG, Chaudhuri D. FGF21 (Fibroblast Growth Factor 21) Defines a Potential Cardiohepatic Signaling Circuit in End-Stage Heart Failure. Circ Heart Fail 2021;:CIRCHEARTFAILURE121008910. [PMID: 34865514 DOI: 10.1161/CIRCHEARTFAILURE.121.008910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Cited by in Crossref: 42] [Cited by in F6Publishing: 56] [Article Influence: 21.0] [Reference Citation Analysis]
26 Wang QJ, Guo Y, Yao CY, Zhang KH, Li Q, Shan CH, Liu P, Wang MZ, Zhu F, An L, Tian JH, Wu ZH. Loss of diurnal behavioral rhythms and impaired lipid metabolism in growing pigs with mistimed feeding. FASEB J 2021;35:e21972. [PMID: 34613642 DOI: 10.1096/fj.202100768R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Shao W, Jin T. Hepatic hormone FGF21 and its analogues in clinical trials. Chronic Diseases and Translational Medicine 2021. [DOI: 10.1016/j.cdtm.2021.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Eder K, Gessner DK, Ringseis R. Fibroblast growth factor 21 in dairy cows: current knowledge and potential relevance. J Anim Sci Biotechnol 2021;12:97. [PMID: 34517929 DOI: 10.1186/s40104-021-00621-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Rader DJ, Maratos-Flier E, Nguyen A, Hom D, Ferriere M, Li Y, Kompa J, Martic M, Hinder M, Basson CT, Yowe D, Diener J, Goldfine AB; CLLF580X2102 study team. LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia. J Clin Endocrinol Metab 2021:dgab624. [PMID: 34431493 DOI: 10.1210/clinem/dgab624] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
30 Dorval L, Knapp BI, Majekodunmi OA, Eliseeva S, Bidlack JM. Mice with High FGF21 Serum Levels Had a Reduced Preference for Morphine and an Attenuated Development of Acute Antinociceptive Tolerance and Physical Dependence.. [DOI: 10.1101/2021.07.30.453845] [Reference Citation Analysis]
31 Sommakia S, Almaw NH, Lee SH, Ramadurai DKA, Taleb I, Kyriakopoulos CP, Stubben CJ, Ling J, Campbell RA, Alharethi RA, Caine WT, Navankasattusas S, Hoareau GL, Abraham AE, Fang JC, Selzman CH, Drakos SG, Chaudhuri D. FGF21 defines a potential cardio-hepatic signaling circuit in human heart failure.. [DOI: 10.1101/2021.06.29.21259720] [Reference Citation Analysis]
32 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Orekhov AN. Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases. Int J Mol Sci 2021;22:6949. [PMID: 34203309 DOI: 10.3390/ijms22136949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Hua S, Liu Q, Li J, Fan M, Yan K, Ye D. Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies. Rev Endocr Metab Disord 2021. [PMID: 34120289 DOI: 10.1007/s11154-021-09661-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Fallowfield JA, Jimenez-Ramos M, Robertson A. Emerging synthetic drugs for the treatment of liver cirrhosis. Expert Opin Emerg Drugs 2021;26:149-63. [PMID: 33856246 DOI: 10.1080/14728214.2021.1918099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Yan J, Nie Y, Cao J, Luo M, Yan M, Chen Z, He B. The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases. Front Cardiovasc Med 2021;8:655575. [PMID: 33869312 DOI: 10.3389/fcvm.2021.655575] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
36 Flippo KH, Potthoff MJ. Metabolic Messengers: FGF21. Nat Metab 2021;3:309-17. [PMID: 33758421 DOI: 10.1038/s42255-021-00354-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 26.0] [Reference Citation Analysis]
37 Luo Y, Li X, Ma J, Abbruzzese JL, Lu W. Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity. Cancers (Basel) 2021;13:778. [PMID: 33668583 DOI: 10.3390/cancers13040778] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Talukdar S, Kharitonenkov A. FGF19 and FGF21: In NASH we trust. Mol Metab 2021;46:101152. [PMID: 33383173 DOI: 10.1016/j.molmet.2020.101152] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
39 Finan B, Parlee SD, Yang B. Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. Mol Metab 2021;46:101153. [PMID: 33359400 DOI: 10.1016/j.molmet.2020.101153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Henriksson E, Andersen B. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. Front Endocrinol (Lausanne) 2020;11:601349. [PMID: 33414764 DOI: 10.3389/fendo.2020.601349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
41 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 15.7] [Reference Citation Analysis]